label: url

en: In vivo drug screening method of radiosensitizers using tumor-bearing chick embryo

en: Elsevier

ja: Elsevier

en: In radiotherapy, tumor hypoxia is the main factor responsible for treatment resistance, and the development of radiosensitizers that can overcome this is imperative. However, many drugs that are effective in vitro and in vivo fail in clinical trials, and thus it is necessary to develop an animal model that can be used for the correct evaluation of pharmacokinetics and activity. Developing chicken eggs are commonly used in various research fields such as anticancer drug sensitivity tests and cardiotoxicity tests. We examined whether the radiosensitizing activity of etanidazole, as a hypoxic cell radiosensitizer, could be evaluated using tumor-bearing chick embryo. Following the transplantation of mouse mammary carcinoma EMT6 cells on day 11, a solid tumor was formed on day 15 and an evaluation of the time-course of the tumor revealed that the tumor weight was the highest on day 18. The maximum dose of etanidazole that did not affect tumor growth and fetal survival was 1.0mg and the maximum X-ray dose was 8Gy. Etanidazole was intravenously administered 10min prior to single dose X-ray irradiation. A significant tumor growth inhibitory effect was confirmed with 1.0mg of etanidazole in combination with 8Gy X-ray. In the case of mouse colon cancer colon26 cells, the combination of 3.0mg of etanidazole and 2Gy X-ray showed 2.79 times higher radiosensitizing activity than that observed for the control group. These results demonstrate that it is possible to evaluate the activity of radiosensitizers using tumor-bearing chick embryo.


en: 酸素をターゲットとしたがんの治療

ja: 酸素をターゲットとしたがんの治療

en: 朝倉書店

ja: 朝倉書店


en: ハイポキシアを標的とした抗癌剤

ja: ハイポキシアを標的とした抗癌剤

en: YODOSHA CO., LTD.

ja: 株式会社 羊土社


en: 酸化ストレスを標的とした薬剤・治療法

ja: 酸化ストレスを標的とした薬剤・治療法

en: 株式会社 診断と治療社

ja: 株式会社 診断と治療社